Min-Sun Park

Min-Sun Park is a Senior Computational Chemist at Superluminal Medicines, Inc. since July 2023, focusing on computational methods for hit discovery and optimization targeting GPCRs. Prior to this role, Min-Sun served as a Staff Scientist at 1859 Inc., enhancing small molecule screening through computational structure-based virtual screening. Previous experience includes positions as a Structural Biologist III at Ambry Genetics, where Min-Sun interpreted genetic variations via protein structure analysis, and as a Scientist I at REG Life Sciences, engineering enzymes for industrial applications. Additional roles include postdoctoral research on membrane proteins at the Howard Hughes Medical Institute, and research associateships at the University of Washington, University of Rochester Medical Center, and Texas A&M University, with a foundation in enzymology and drug screening. Min-Sun holds a Ph.D. in Biophysics from the University of Rochester School of Medicine and Dentistry and a Master’s Degree in Bio-organic Chemistry from Texas A&M University.